Parabolic Drugs Ltd
PARABDRUGS Share Price
How to use scorecard? Learn more
PARABDRUGS Performance & Key Metrics
PARABDRUGS Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| — | -0.04 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 35.65 | 6.55 | 0.85% |
PARABDRUGS Analyst Ratings & Forecast
Price Upside
Earnings Growth
Rev. Growth
PARABDRUGS Company Profile
Parabolic Drugs Limited is an integrated, research-based, pharmaceutical manufacturer and exporter, engaged in development and manufacturing of Active Pharmaceutical Ingredients (API) and API intermediates.
PARABDRUGS Sentiment Analysis
PARABDRUGS Sentiment Analysis
PARABDRUGS Stock Summary · January 2025
Company is navigating a complex landscape characterized by declining market share in deposits, challenges in meeting Priority Sector Lending (PSL) obligations, and fluctuations in current account flows. Despite these hurdles, the bank is focusing on enhancing customer engagement and service delivery to drive deposit growth, with recent monthly inflows showing a positive trend. The management emphasizes a strategic approach to maintaining profitability over aggressive expansion, particularly in light of competitive pressures and a tight liquidity environment. Efforts to improve operational efficiencies through digitization and a commitment to stable cost management are underway, alongside a proactive strategy to reduce borrowings and strengthen the balance sheet. Overall, while facing short-term challenges, the bank remains optimistic about future performance and is committed to achieving sustainable growth through strategic investments and improved customer outreach.
PARABDRUGS Stock Growth Drivers
PARABDRUGS Stock Growth Drivers
4Focus on Sustainable Growth
Company is prioritizing profitable growth over mere expansion, emphasizing a strategy that encourages ground-level teams
Stable Financial Metrics
The company has maintained a return on assets (ROA) of 1.9% post-merger, showcasing stability in
PARABDRUGS Stock Challenges
PARABDRUGS Stock Challenges
5Deposit Growth Shortfalls
The company has experienced deposit growth that has not met expectations, attributed to seasonal trends
Loan Growth Concerns
There is uncertainty regarding the company's loan deposit ratio (LDR) and its implications for loan
PARABDRUGS Forecast
What are forecasts?
What are forecasts?
Forecasting uses historical data as inputs to make informed predictive estimates determining the direction of future trends. Price, revenue & earnings forecasts represent where the stock level, business prospects and profits are potentially expected to be at the end of the forecast period
PARABDRUGS Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
PARABDRUGS
PARABDRUGS
Income
Balance Sheet
Cash Flow
PARABDRUGS Income Statement
PARABDRUGS Income Statement
| Financial Year | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 928.42 | 772.88 | 450.63 | 233.38 | 77.16 | 81.10 | 77.32 | 18.89 | 0.02 | — | ||||||||||
Raw Materials | 800.45 | 691.04 | 391.42 | 209.02 | 59.07 | 64.87 | 64.60 | 34.72 | 6.41 | — | ||||||||||
| Power & Fuel Cost | 9.81 | 10.02 | 17.22 | 15.26 | 10.17 | 8.97 | 6.87 | |||||||||||||
| Employee Cost | 22.52 | 23.75 | 19.23 | 17.46 | 10.91 | 9.03 | 9.83 | |||||||||||||
| Selling & Administrative Expenses | 23.31 | 25.55 | 20.69 | 14.06 | 8.69 | 6.07 | 5.77 | |||||||||||||
| Operating & Other expenses | -89.09 | 94.75 | 72.20 | 55.52 | 294.74 | 32.58 | 2.20 | |||||||||||||
EBITDA | 161.42 | -72.23 | -70.13 | -77.94 | -306.42 | -40.42 | -11.95 | -15.83 | -6.39 | — | ||||||||||
| Depreciation/Amortization | 30.85 | 55.19 | 68.25 | 73.20 | 67.22 | 53.65 | 34.54 | 22.52 | 21.59 | — | ||||||||||
| PBIT | 130.57 | -127.42 | -138.38 | -151.14 | -373.64 | -94.07 | -46.49 | -38.35 | -27.98 | — | ||||||||||
| Interest & Other Items | 64.14 | 73.24 | 83.70 | 98.99 | 107.62 | 10.97 | 9.30 | 3.46 | 0.66 | — | ||||||||||
| PBT | 66.43 | -200.66 | -222.08 | -250.13 | -481.26 | -105.04 | -55.79 | -41.81 | -28.64 | — | ||||||||||
| Taxes & Other Items | 15.23 | -56.17 | -88.28 | 130.32 | 4.43 | 3.05 | 1.76 | -0.41 | 0.00 | — | ||||||||||
| Net Income | 51.20 | -144.49 | -133.80 | -380.45 | -485.69 | -108.09 | -57.55 | -41.40 | -28.64 | — | ||||||||||
| EPS | 8.27 | -23.35 | -21.62 | -61.47 | -78.47 | -17.46 | -9.30 | -6.57 | -4.63 | — | ||||||||||
| DPS | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — | ||||||||||
| Payout ratio | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
PARABDRUGS Company Updates
PARABDRUGS Stock Peers
What are peers and why compare against them?
What are peers and why compare against them?
A stock's peers are companies which have similar business interests, operations and belong to the same industry sector. Comparing various metrics against peers can give valuable insights on whether the company's stock is over/under-valued and the company's growth outlook vs the industry as a whole
PARABDRUGS Past Performance & Peer Comparison
PARABDRUGS Past Performance & Peer Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation-basic on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Parabolic Drugs Ltd | -1.19 | -0.04 | — |
| Sun Pharmaceutical Industries Ltd | 36.18 | 5.89 | 0.97% |
| Cipla Ltd | 22.95 | 4.51 | 1.07% |
| Dr Reddy's Laboratories Ltd | 19.32 | 3.87 | 0.61% |
PARABDRUGS Stock Price Comparison
Compare PARABDRUGS with any stock or ETFPARABDRUGS Holdings
PARABDRUGS Shareholdings
What are shareholdings?
What are shareholdings?
Apart from retail investors, a company’s shares are held by promoters, foreign & domestic institutions (large investors) and mutual funds. Promoters are the ship captains and control the company’s direction. Along with institutional and mutual fund holdings, a change in their holdings can indicate performance outlook for the stock
PARABDRUGS Promoter Holdings Trend
PARABDRUGS Promoter Holdings Trend
PARABDRUGS Institutional Holdings Trend
PARABDRUGS Institutional Holdings Trend
In last 3 months, retail holding in the company has almost stayed constant
In last 3 months, foreign institutional holding of the company has almost stayed constant
PARABDRUGS Shareholding Pattern
PARABDRUGS Shareholding Pattern
PARABDRUGS Shareholding History
PARABDRUGS Shareholding History
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing PARABDRUGS stock
smallcases containing PARABDRUGS stock
Looks like this stock is not in any smallcase yet.
PARABDRUGS Events
PARABDRUGS Events
PARABDRUGS Dividend Trend
PARABDRUGS has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
What are dividends?
What are dividends?
Dividends are a portion of earnings that a company distributes to all its shareholders every year. Dividend return is one of the most important things to be considered while investing for long term. It’s the additional return on top of what investors earn through price appreciation
PARABDRUGS Dividend Trend
PARABDRUGS has not given any dividends in last 5 years
PARABDRUGS Upcoming Dividends
PARABDRUGS Upcoming Dividends
No upcoming dividends are available
PARABDRUGS Past Dividends
PARABDRUGS Past Dividends
Cash Dividend
Ex DateEx DateSep 24, 2012
Dividend/Share
₹0.25
Ex DateEx Date
Sep 24, 2012
Cash Dividend
Ex DateEx DateSep 19, 2011
Dividend/Share
₹0.50
Ex DateEx Date
Sep 19, 2011
In last 6 months, promoter holding in the company has almost stayed constant
A significant proportion of promoter holdings is pledged